Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Collaborators: Eli Lilly and Company; German Hodgkin's Lymphoma Study Group
• Treatments: Doxorubicin; Gemcitabine; Liposomal doxorubicin; Prednisone; Vinblastine

Criteria

Inclusion Criteria:

• Hodgkin's lymphoma (histologically proven)

• Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal involvement), III, or IV

• No prior antitumor therapy

• Age 60 to 75 years

• WHO performance status 0-2

• Normal pulmonary function

• Written informed consent

Exclusion Criteria:

• The following histologies are excluded: lymphocyte predominant HD

• Leukocytes < 2,500/microL

• Platelets < 100,000/microL